ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET

PRINCETON, N.J., Oct. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its third quarter 2026 financial results on Thursday, November 5, 2026, at 8:00 a.m. ET.

GlobeNewsWire • Oct 23, 2026

ANI Pharmaceuticals Announces the Launch of Duloxetine Delayed-Release Capsules

PRINCETON, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Duloxetine Delayed-Release Capsules 20, 30 and 60 mg. ANI's Duloxetine Delayed-Release Capsules are the generic version of the reference listed drug (RLD) Cymbalta®.

GlobeNewsWire • Oct 19, 2026

Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 13, 2026

ANI Pharmaceuticals Announces New Fluocinolone Acetonide Intravitreal Implant Data to be Presented at the American Academy of Ophthalmology 2026 Annual Meeting

Data from Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day 2026

GlobeNewsWire • Sep 30, 2026

Implied Volatility Surging for ANI Pharmaceuticals Stock Options

Investors need to pay close attention to ANIP stock based on the movements in the options market lately.

Zacks Investment Research • Sep 28, 2026

ANI Pharmaceuticals: Cortrophin's Q4 Test, With Generics Funding The Build

ANI Pharmaceuticals is rated Buy, with a fair value of $104, offering 38% upside from current levels. Generics generate strong EBITDA and cash, funding rare-disease expansion; rare disease is expected to comprise nearly 60% of 2026 revenue. Cortrophin guidance was lowered by ~$30M, but H2 expectations remain intact, with Q4 growth hinging on gout salesforce productivity.

Seeking Alpha • Sep 24, 2026

ANI Pharmaceuticals Announces the FDA Approval of Everolimus Tablets for Oral Suspension

PRINCETON, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), for Everolimus Tablets for Oral Suspension 2mg, 3mg and 5mg. ANI's Everolimus Tablets for Oral Suspension are the generic version of the reference listed drug (RLD) Afinitor Disperz®.

GlobeNewsWire • Sep 23, 2026

ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha • Sep 14, 2026

ANI Pharmaceuticals to Present at September Investor Conferences

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team, will participate in fireside chats at the following upcoming investor conferences:

GlobeNewsWire • Sep 3, 2026

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

– Appointment strengthens board as ANI accelerates transformation into a leading Rare Disease Company – PRINCETON, N.J., Aug. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today reported the addition of Henry Gosebruch to its Board of Directors effective August 19, 2026.

GlobeNewsWire • Aug 24, 2026